What is Gritstone Bio?
Headquartered in Emeryville, California, Gritstone Bio specializes in the development of groundbreaking immunotherapies designed to address complex challenges in cancer treatment and infectious disease management. By leveraging advanced antigen discovery and vaccine technology, the company occupies a critical niche in the biopharmaceutical landscape. Its operational model focuses on translating scientific discovery into clinical-stage assets, supported by a robust ecosystem of venture capital partners and life science investors who prioritize long-term therapeutic breakthroughs.
How much funding has Gritstone Bio raised?
Gritstone Bio has raised a total of $472.1M across 5 funding rounds:
Series A
$102M
Series B
$92.7M
Stock Offering
$92.6M
Stock Offering
$74.8M
Share Placement
$110M
Series A (2015): $102M with participation from Versant Ventures, Casdin Capital, The Column Group, Frazier Healthcare Partners, Clarus Ventures, Transformational Healthcare Opportunity, and Redmile Group
Series B (2017): $92.7M led by The Column Group, Trinitas Capital Management, Frazier Healthcare Partners, Versant Ventures, Alexandria Venture Investments, GV, Clarus Funds, and Lilly Asia Ventures
Stock Issuance/Offering (2018): $92.6M supported by Undisclosed
Stock Issuance/Offering (2019): $74.8M featuring Undisclosed
Share Placement (2020): $110M backed by Redmile Group, EcoR1 Capital, and Avidity Partners
Key Investors in Gritstone Bio
The Column Group
A venture ecosystem focused on advancing scientific innovation in the life sciences sector, supporting the formation and growth of numerous biotechnology companies.
Versant Ventures
A global venture capital firm with extensive experience in biotechnology, managing significant assets to fund innovative companies and drive scientific discoveries.
Redmile Group
A specialized investment firm operating within the venture capital and private equity space, known for its focus on high-growth healthcare and life science enterprises.
What's next for Gritstone Bio?
Following the recent strategic financing, Gritstone Bio is well-positioned to accelerate its clinical development programs. The influx of capital provides the necessary runway to advance its lead candidates through rigorous testing phases and expand its research capabilities. As the company transitions further into late-stage development, the focus will likely shift toward commercialization readiness and the potential for strategic partnerships to scale its therapeutic impact. Investors remain focused on the firm's ability to deliver clinical data that validates its unique approach to molecular disease intervention.
See full Gritstone Bio company page
